Midazolam Aguettant: Uses, Dosage & Side Effects
A short-acting benzodiazepine solution for sedation, anaesthesia premedication, and emergency seizure management in hospital and supervised clinical settings
Midazolam Aguettant is a prescription benzodiazepine solution containing midazolam at a concentration of 1 mg/ml, manufactured by Laboratoire Aguettant. Midazolam is one of the most widely used short-acting benzodiazepines in clinical medicine, employed for conscious sedation during diagnostic and therapeutic procedures, premedication before general anaesthesia, sedation in intensive care units, and as an emergency treatment for prolonged convulsive seizures (status epilepticus). It acts by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system, producing rapid sedation, anxiolysis, amnesia, and anticonvulsant effects. Due to the risk of respiratory depression, midazolam must only be administered by experienced clinicians in settings equipped for continuous cardiorespiratory monitoring and resuscitation.
Quick Facts: Midazolam Aguettant
Key Takeaways
- Midazolam Aguettant is a short-acting benzodiazepine (1 mg/ml solution) used for procedural sedation, premedication before anaesthesia, ICU sedation, and emergency treatment of prolonged seizures in both adults and children.
- It has a rapid onset of action (1–5 minutes IV, 5–15 minutes IM) and a short elimination half-life of approximately 1.5–2.5 hours, making it ideal for procedures requiring predictable sedation duration.
- Respiratory depression is the most serious risk, especially when combined with opioids or in elderly, debilitated, or hepatically impaired patients – continuous monitoring of breathing and oxygen saturation is mandatory.
- Midazolam is extensively metabolized by the cytochrome P450 enzyme CYP3A4, leading to clinically significant drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) and inducers (e.g., rifampicin).
- Flumazenil is the specific benzodiazepine antagonist available to reverse midazolam overdose, but it must be used with caution in patients with benzodiazepine dependence or seizure history.
What Is Midazolam Aguettant and What Is It Used For?
Midazolam Aguettant contains the active substance midazolam (present as midazolam hydrochloride), a water-soluble benzodiazepine derivative that belongs to the imidazobenzodiazepine class of psychoactive drugs. Midazolam was first synthesized in 1975 and approved for clinical use in the 1980s, rapidly becoming one of the most widely used sedative agents in anaesthesiology, emergency medicine, and critical care worldwide. The Aguettant formulation provides midazolam at a concentration of 1 mg/ml, specifically designed for precise dose titration during parenteral administration.
The pharmacological effects of midazolam are mediated through its interaction with the gamma-aminobutyric acid type A (GABAA) receptor, the principal inhibitory neurotransmitter receptor in the mammalian central nervous system. The GABAA receptor is a ligand-gated chloride ion channel composed of five protein subunits. Benzodiazepines, including midazolam, bind to a specific allosteric site located at the interface between the alpha and gamma subunits of the receptor. This binding does not directly activate the receptor but rather enhances the effect of endogenous GABA by increasing the frequency of chloride channel opening when GABA binds to its own site on the receptor. The resulting increase in chloride ion influx into neurons causes hyperpolarization of the neuronal membrane, making the neuron less excitable and thereby producing a spectrum of pharmacological effects including sedation, anxiolysis, anterograde amnesia, skeletal muscle relaxation, and anticonvulsant activity.
One of the distinctive pharmacokinetic properties of midazolam is its water solubility at acidic pH (below 4), which makes it suitable for injection without the need for organic solvents such as propylene glycol (which is required for diazepam injection and can cause pain and thrombophlebitis). At physiological pH (approximately 7.4), the imidazole ring of midazolam closes, rendering the molecule highly lipophilic. This pH-dependent lipophilicity allows midazolam to rapidly cross the blood-brain barrier after intravenous injection, resulting in an onset of sedation within 1 to 5 minutes. The rapid onset combined with a relatively short duration of action (elimination half-life of 1.5 to 2.5 hours in healthy adults) makes midazolam particularly well-suited for procedural sedation and short-term clinical applications.
Midazolam Aguettant is indicated for several clinical applications, each reflecting the drug’s rapid onset, predictable duration, and versatile routes of administration:
- Conscious sedation for diagnostic and therapeutic procedures: Midazolam is used to produce a state of calm, relaxation, and reduced awareness during procedures such as endoscopy, bronchoscopy, cardiac catheterization, dental procedures, and minor surgical interventions. During conscious sedation, the patient maintains protective reflexes and can respond to verbal commands, but experiences reduced anxiety and often has no memory of the procedure (anterograde amnesia).
- Premedication before surgical anaesthesia: Administered before induction of general anaesthesia to reduce preoperative anxiety, produce sedation, and facilitate smooth induction. The amnestic properties of midazolam are particularly valued in this context, as they reduce the patient’s recall of unpleasant preoperative experiences.
- Induction of general anaesthesia: In certain clinical situations, midazolam can be used as an induction agent for general anaesthesia, particularly in combination with other anaesthetic agents. However, it is less commonly used for induction compared with propofol or thiopental due to its longer onset time and less predictable induction characteristics.
- Sedation in intensive care units (ICU): Midazolam is widely used for sedation of mechanically ventilated patients in intensive care units. It can be administered as a continuous intravenous infusion, titrated to achieve the desired level of sedation while maintaining haemodynamic stability. However, current intensive care guidelines increasingly favour shorter-acting agents such as propofol or dexmedetomidine for ICU sedation to reduce the risk of prolonged sedation and delirium.
- Treatment of prolonged acute convulsive seizures (status epilepticus): Midazolam is an effective anticonvulsant and is used as a first-line or second-line treatment for prolonged seizures, particularly via the buccal or intramuscular route when intravenous access is not immediately available. Buccal midazolam has become a standard emergency treatment for prolonged seizures in children and is widely used in pre-hospital settings.
The clinical utility of midazolam has been established through decades of clinical experience and numerous randomized controlled trials. The World Health Organization (WHO) includes midazolam on its Model List of Essential Medicines, recognizing it as one of the most important medications needed in a basic health system. Its inclusion reflects the drug’s proven efficacy, acceptable safety profile when used appropriately, and its role in addressing critical clinical needs in anaesthesia, sedation, and seizure management worldwide.
The World Health Organization lists midazolam as an essential medicine for its established roles in anaesthesia, sedation, and seizure management. Its unique combination of water solubility (allowing painless injection), rapid onset, short duration, potent amnesia, and anticonvulsant activity makes it indispensable in modern clinical practice. The 1 mg/ml concentration of Midazolam Aguettant is specifically designed for situations requiring precise dose titration, particularly in paediatric patients and procedural sedation.
What Should You Know Before Taking Midazolam Aguettant?
Contraindications
Midazolam Aguettant must not be used in the following situations. The contraindications are based on the pharmacological properties of midazolam and the potential for serious, life-threatening adverse effects in susceptible individuals:
- Hypersensitivity: Known allergy to midazolam, other benzodiazepines, or any of the excipients in the formulation. Anaphylactic reactions to benzodiazepines, while rare, have been reported and can be life-threatening.
- Severe respiratory insufficiency: Midazolam depresses respiratory drive and must not be used in patients with severe respiratory failure or acute respiratory depression, as it may precipitate respiratory arrest.
- Myasthenia gravis: The muscle-relaxant properties of benzodiazepines can worsen the muscle weakness characteristic of this autoimmune neuromuscular disorder, potentially leading to respiratory failure.
- Severe hepatic insufficiency: Midazolam is extensively metabolized by the liver, and patients with severe hepatic impairment may accumulate the drug to dangerous levels, leading to prolonged and excessive sedation.
- Sleep apnoea syndrome: Midazolam can exacerbate obstructive sleep apnoea by relaxing upper airway muscles and depressing the central respiratory drive, increasing the risk of airway obstruction and hypoxia.
- Conscious sedation in patients unable to be monitored: Midazolam for conscious sedation must only be used where appropriate monitoring of respiratory and cardiac function is available. It must not be administered for sedation outside of supervised medical settings.
Warnings and Precautions
Midazolam can cause life-threatening respiratory depression, airway obstruction, and apnoea, particularly when administered intravenously, at high doses, or in combination with opioid analgesics. Fatalities have been reported. Administration must only be performed by physicians experienced in sedation/anaesthesia, with continuous pulse oximetry monitoring, and with immediate access to resuscitation equipment including oxygen, suction, bag-valve-mask ventilation, endotracheal intubation equipment, and flumazenil (benzodiazepine antagonist).
The following precautions must be observed when using Midazolam Aguettant:
- Risk of respiratory depression with opioids: The concomitant use of midazolam with opioid analgesics (such as fentanyl, morphine, or remifentanil) significantly increases the risk of profound sedation, respiratory depression, coma, and death. When co-administration is clinically necessary, both drugs should be used at the lowest effective doses, the duration of treatment should be minimized, and patients must be closely monitored for signs of respiratory depression and excessive sedation. The FDA and EMA have issued boxed warnings regarding this combination.
- Elderly patients: Older adults are significantly more sensitive to the sedative and respiratory depressant effects of midazolam. The elimination half-life is prolonged in elderly patients (up to 5–6 hours), and the dose requirement is typically 50% lower than in younger adults. Careful dose titration with slower injection rates is essential.
- Hepatic impairment: Midazolam is extensively metabolized by the liver via CYP3A4. Patients with hepatic cirrhosis or other forms of hepatic impairment will have significantly prolonged elimination half-lives and increased sensitivity to the drug. Dose reduction and careful monitoring are required.
- Renal impairment: Although midazolam itself is primarily eliminated via hepatic metabolism, its pharmacologically active metabolite alpha-hydroxymidazolam is renally excreted. In patients with severe renal failure (particularly in the ICU setting), accumulation of this metabolite can lead to prolonged sedation.
- Chronic respiratory disease: Patients with chronic obstructive pulmonary disease (COPD) or other chronic respiratory conditions are at increased risk of respiratory depression. Lower doses and careful monitoring are required.
- Risk of physical dependence and withdrawal: Prolonged use of midazolam (particularly in the ICU setting) can lead to physical dependence. Abrupt discontinuation after prolonged use may precipitate benzodiazepine withdrawal syndrome, characterized by anxiety, insomnia, tremors, and in severe cases, seizures. Gradual dose tapering is recommended.
- Paradoxical reactions: In some patients, particularly children and elderly individuals, midazolam may cause paradoxical reactions including agitation, involuntary movements, hyperactivity, hostility, rage, and aggression. These reactions are more common with rapid injection, higher doses, and in paediatric populations. If paradoxical reactions occur, the administration should be discontinued.
Pregnancy and Breastfeeding
Midazolam crosses the placenta and can affect the fetus, particularly when administered during the third trimester or during labour. Use of benzodiazepines during the third trimester has been associated with neonatal respiratory depression, hypotonia (floppy infant syndrome), hypothermia, poor feeding, and, in cases of prolonged maternal use, neonatal withdrawal syndrome. Midazolam should be avoided during pregnancy unless there is no suitable alternative and the clinical benefit clearly outweighs the risk to the fetus. If midazolam must be administered near term or during labour, the neonatal team should be informed and prepared to manage potential neonatal depression.
Midazolam is excreted in human breast milk, although in small quantities. After a single dose of midazolam, breastfeeding can generally be resumed after 4 hours. However, after repeated administration or continuous infusion, breastfeeding should be interrupted until midazolam has been fully eliminated (approximately 24 hours after the last dose). Mothers should be advised to express and discard breast milk during this period.
Effects on Ability to Drive and Use Machines
Midazolam significantly impairs cognitive function, reaction time, and psychomotor performance. Sedation, amnesia, impaired attention, and impaired muscular function may persist for a prolonged period after administration. Patients must not drive, operate machinery, or engage in activities requiring alertness for at least 12 hours after receiving midazolam, or until the effects have fully resolved as assessed by their healthcare provider. Following procedures performed under midazolam sedation, patients must be accompanied home by a responsible adult and should not make important legal decisions for 24 hours.
After receiving midazolam sedation, patients must not drive, operate machinery, or make important decisions for at least 12–24 hours. The amnestic effects of midazolam mean that patients may not remember instructions given immediately after the procedure. Written discharge instructions should always be provided and reviewed with the accompanying responsible adult.
How Does Midazolam Aguettant Interact with Other Drugs?
Unlike some other medications where drug interactions are minimal, midazolam has several clinically important interactions that must be carefully considered before and during administration. These interactions fall into two main categories: pharmacokinetic interactions (affecting how the body processes midazolam) and pharmacodynamic interactions (affecting the body’s response to midazolam in combination with other drugs).
Pharmacokinetic Interactions (CYP3A4 Pathway)
Midazolam is almost exclusively metabolized by the hepatic enzyme cytochrome P450 3A4 (CYP3A4) to its primary metabolite, alpha-hydroxymidazolam, which retains approximately 50% of the pharmacological activity of the parent compound. Drugs that inhibit or induce CYP3A4 can therefore profoundly alter the plasma concentrations and clinical effects of midazolam. This is one of the most well-characterized drug-drug interaction pathways in clinical pharmacology, and midazolam is frequently used as a probe substrate in CYP3A4 interaction studies.
| Drug / Drug Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole, Itraconazole | Strong CYP3A4 inhibitor | 3–5 fold increase in midazolam AUC; prolonged sedation | Reduce dose by 50–75%; close monitoring |
| HIV protease inhibitors (ritonavir, saquinavir) | Strong CYP3A4 inhibitor | Marked increase in midazolam exposure; risk of prolonged coma | IV midazolam in monitored setting only; oral midazolam contraindicated |
| Erythromycin, Clarithromycin | Moderate CYP3A4 inhibitor | 2–3 fold increase in midazolam AUC | Reduce midazolam dose; monitor for prolonged sedation |
| Fluconazole | Moderate CYP3A4 inhibitor | 2–3 fold increase in midazolam AUC | Reduce midazolam dose; extended monitoring |
| Diltiazem, Verapamil | Moderate CYP3A4 inhibitor | Increased midazolam effect and duration | Dose adjustment may be needed |
| Grapefruit juice | CYP3A4 inhibitor (intestinal) | Increased oral midazolam bioavailability (less relevant for IV) | Avoid grapefruit juice with oral midazolam |
| Rifampicin | Strong CYP3A4 inducer | Up to 96% reduction in midazolam AUC; loss of efficacy | Significant dose increase may be needed; monitor response |
| Carbamazepine, Phenytoin | Strong CYP3A4 inducer | Substantially reduced midazolam levels | Higher doses may be required; monitor sedation |
| St John’s Wort | CYP3A4 inducer | Reduced midazolam efficacy | Avoid concomitant use |
Pharmacodynamic Interactions (CNS Depression)
Midazolam has additive or synergistic central nervous system (CNS) depressant effects when combined with other drugs that depress brain function. These pharmacodynamic interactions are clinically significant because they increase the risk of profound sedation, respiratory depression, cardiovascular collapse, and death. The following categories of drugs require particular attention:
- Opioid analgesics: The combination of midazolam with opioids (fentanyl, morphine, remifentanil, alfentanil) is one of the most common and most dangerous drug combinations in anaesthetic practice. While this combination is frequently used intentionally to achieve balanced anaesthesia, it dramatically increases the risk of respiratory depression and apnoea. Doses of both agents should be reduced, and continuous cardiorespiratory monitoring is essential.
- Other sedatives and hypnotics: Propofol, barbiturates, ketamine, and other sedative agents potentiate the CNS depressant effects of midazolam. Dose reductions are required when these agents are used in combination.
- Alcohol (ethanol): Alcohol significantly enhances the sedative, amnestic, and respiratory depressant effects of midazolam. Patients should abstain from alcohol for at least 24 hours before and after receiving midazolam.
- Antipsychotics and antidepressants: Some antipsychotic medications and certain antidepressants (particularly sedating types) can potentiate the CNS depressant effects of midazolam.
- Antihistamines: First-generation (sedating) antihistamines such as diphenhydramine and promethazine may increase sedation when combined with midazolam.
The concurrent use of benzodiazepines (including midazolam) and opioid analgesics increases the risk of profound sedation, respiratory depression, coma, and death. This combination should only be used when alternative treatment options are inadequate, and patients must be monitored for respiratory depression and excessive sedation. Both regulatory agencies have issued their strongest warnings regarding this drug combination.
What Is the Correct Dosage of Midazolam Aguettant?
Midazolam Aguettant (1 mg/ml) should always be used exactly as prescribed by the attending physician. The dose of midazolam must be individualized based on the clinical indication, the route of administration, the patient’s age and body weight, physical status (ASA classification), concomitant medications, and the desired depth and duration of sedation. The fundamental principle of midazolam dosing is to administer the lowest effective dose, titrated slowly to achieve the desired clinical effect. Rapid bolus injection must be avoided as it increases the risk of respiratory depression and apnoea.
Adults (Conscious Sedation for Procedures)
Intravenous Sedation – Adults Under 60 Years
Initial dose: 1–2.5 mg IV, given slowly over 2–3 minutes. Wait at least 2 minutes to evaluate the sedative effect before administering further increments.
Titration: Additional doses of 0.5–1 mg may be given at intervals of at least 2 minutes until adequate sedation is achieved.
Total dose: Usually 2.5–7.5 mg. A total dose exceeding 5 mg is generally not necessary. In ASA III/IV patients or when used with opioids, the initial dose should be reduced to 0.5–1 mg.
Intramuscular Sedation – Adults
Dose: 0.07–0.08 mg/kg (approximately 5 mg in a 70 kg patient), administered 20–30 minutes before the procedure.
Note: IM administration should be reserved for situations where IV access is not available. Onset is slower (5–15 minutes) and less predictable than IV administration.
Premedication Before Anaesthesia – Adults
IV route: 1–2 mg, repeated as necessary. Administered 5–10 minutes before induction.
IM route: 0.07–0.1 mg/kg, administered 20–60 minutes before induction of anaesthesia.
ICU Sedation – Adults
Loading dose: 0.03–0.3 mg/kg IV, given slowly in increments of 1–2.5 mg over 2–3 minutes per increment.
Maintenance infusion: 0.03–0.2 mg/kg/hour. The infusion rate should be titrated to the desired sedation level using validated sedation scales (e.g., RASS or Ramsay scale).
Note: Current ESICM and SCCM guidelines recommend limiting benzodiazepine-based sedation in ICU patients due to the association with increased delirium, prolonged mechanical ventilation, and longer ICU stays compared with propofol or dexmedetomidine.
Children
Children are generally more sensitive to the effects of midazolam, and dosing must be carefully adjusted based on age and body weight. All paediatric doses should be administered with continuous monitoring of respiratory and cardiac function:
| Indication | Age Group | Route | Dose |
|---|---|---|---|
| Conscious sedation | 6 months – 5 years | IV | 0.05–0.1 mg/kg; total dose usually ≤6 mg |
| Conscious sedation | 6–12 years | IV | 0.025–0.05 mg/kg; total dose usually ≤10 mg |
| Premedication | 1–15 years | IM | 0.08–0.2 mg/kg |
| Premedication | 1–15 years | Rectal | 0.3–0.5 mg/kg |
| Prolonged seizures | 3 months – <1 year | Buccal | 2.5 mg |
| Prolonged seizures | 1–4 years | Buccal | 5 mg |
| Prolonged seizures | 5–9 years | Buccal | 7.5 mg |
| Prolonged seizures | ≥10 years | Buccal | 10 mg |
| ICU sedation | Neonates ≤32 weeks | IV infusion | 0.03 mg/kg/hour |
| ICU sedation | Neonates >32 weeks – 6 months | IV infusion | 0.06 mg/kg/hour |
| ICU sedation | >6 months | IV infusion | 0.06–0.12 mg/kg/hour |
Elderly Patients (≥60 Years)
Elderly patients are significantly more sensitive to the effects of midazolam due to age-related changes in pharmacokinetics (reduced hepatic blood flow, decreased CYP3A4 activity, increased volume of distribution) and pharmacodynamics (increased receptor sensitivity). The elimination half-life of midazolam in elderly patients may be 2–3 times longer than in younger adults. The initial IV dose for conscious sedation should be reduced to 0.5–1 mg, given slowly, with at least 2–3 minutes between increments. The total dose required is typically 50% lower than in younger adults. Elderly patients must be monitored for a longer period after midazolam administration.
Missed Dose
Midazolam Aguettant is not a medication that is taken on a regular schedule by patients at home. It is administered by healthcare professionals in clinical settings on an as-needed basis. Therefore, the concept of a “missed dose” does not apply in the usual sense. If a planned dose for a procedure or scheduled sedation session is not given, the healthcare team will determine the appropriate timing for the next administration based on the clinical situation.
Overdose
Overdose of midazolam manifests primarily as excessive and prolonged CNS depression, including deep sedation, coma, respiratory depression, apnoea, hypotension, and cardiovascular collapse. In severe cases, overdose can be fatal, particularly when midazolam is combined with opioids or other CNS depressants.
The management of midazolam overdose includes:
- Airway management: Ensure a patent airway, provide supplemental oxygen, and initiate assisted ventilation (bag-valve-mask or endotracheal intubation) if necessary.
- Flumazenil (Anexate): Flumazenil is the specific benzodiazepine antagonist that competitively blocks benzodiazepine binding at the GABAA receptor. The recommended initial dose is 0.2 mg IV over 15 seconds. If the desired level of consciousness is not obtained within 60 seconds, a further 0.1 mg can be given at 60-second intervals up to a total dose of 1–2 mg. Flumazenil has a shorter duration of action than midazolam, so re-sedation may occur and repeated doses or continuous infusion of flumazenil may be necessary.
- Caution with flumazenil: Flumazenil must be used with caution in patients who have received benzodiazepines for seizure control (risk of recurrent seizures), in patients with benzodiazepine dependence (risk of acute withdrawal including seizures), and in patients who have co-ingested proconvulsant drugs (e.g., tricyclic antidepressants).
- Supportive care: Continuous monitoring of vital signs, haemodynamic support with IV fluids and vasopressors if needed, and monitoring in an intensive care setting until full recovery.
Flumazenil is the specific reversal agent for benzodiazepine overdose and is included on the WHO Model List of Essential Medicines. It should be immediately available whenever midazolam is administered. However, flumazenil’s shorter half-life (40–80 minutes) compared with midazolam means re-sedation can occur, requiring repeated dosing or continuous infusion and extended patient observation.
What Are the Side Effects of Midazolam Aguettant?
Like all medicines, Midazolam Aguettant can cause side effects, although not everybody gets them. The side effects of midazolam are generally dose-dependent and are most pronounced during and immediately after administration. The frequency and severity of side effects are influenced by the route and speed of administration, the total dose, concomitant medications (especially opioids), and patient-specific factors including age, hepatic function, and overall clinical condition.
The following side effects have been reported with midazolam, classified according to their frequency based on clinical trial data and post-marketing surveillance reports:
Very Common (>1/10)
- Drowsiness and prolonged sedation
- Reduced alertness and attention
- Anterograde amnesia (inability to form new memories after administration; duration depends on dose and may persist for several hours)
Common (1/10 – 1/100)
- Headache
- Dizziness
- Confusion and disorientation
- Nausea and vomiting
- Injection site reactions (pain, redness, thrombophlebitis)
- Fatigue
- Hiccups (particularly during endoscopy procedures)
Uncommon (1/100 – 1/1,000)
- Paradoxical reactions (agitation, involuntary movements, hyperactivity, hostility, rage, aggression – more common in children and elderly)
- Hallucinations
- Skin rash, urticaria (hives), pruritus (itching)
- Respiratory depression (dose-dependent; risk significantly increased with opioid co-administration)
- Hypotension (low blood pressure)
- Bradycardia (slow heart rate)
- Dry mouth
- Constipation
Rare (<1/1,000)
- Anaphylactic/anaphylactoid reactions
- Angioedema
- Cardiac arrest (predominantly in combination with opioids or rapid IV injection)
- Respiratory arrest and apnoea (particularly with rapid IV injection, high doses, or opioid co-administration)
- Laryngospasm
- Physical dependence and withdrawal syndrome (after prolonged ICU use)
- Drug abuse and dependence (controlled substance)
Not Known (Frequency Cannot Be Estimated)
- Neonatal withdrawal syndrome (after maternal use during third trimester)
- Falls and fractures (particularly in elderly, due to sedation and muscle relaxation)
- Retrograde amnesia (rare; loss of memory for events before administration)
- Movement disorders (dyskinesia, athetoid movements)
If you experience any side effects after receiving midazolam, particularly difficulty breathing, severe allergic reactions (swelling of the face, lips, or throat), or prolonged confusion, inform your healthcare provider immediately. In a clinical setting, these effects are typically monitored for and managed proactively. Healthcare professionals should report any suspected adverse reactions through the applicable national pharmacovigilance reporting system.
After receiving midazolam, seek immediate medical attention if you experience: difficulty breathing or noisy breathing, blue discolouration of the lips or fingernails, severe drowsiness that you cannot be woken from, swelling of the face, lips or throat, chest pain or irregular heartbeat, or seizures. If you are a caregiver observing a patient who has received midazolam, call for emergency medical help if the patient cannot be roused or if breathing becomes irregular or stops.
How Should You Store Midazolam Aguettant?
Proper storage of Midazolam Aguettant is essential to maintain the stability, sterility, and efficacy of the solution. As a parenteral pharmaceutical product, the storage conditions must comply with the manufacturer’s specifications and local pharmaceutical regulations. Midazolam Aguettant is typically supplied in single-use glass ampoules or prefilled syringes, which are designed for immediate use in clinical settings.
The following storage guidelines apply to Midazolam Aguettant:
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze, as freezing may affect the integrity of the container and the physicochemical properties of the solution.
- Light protection: Keep the ampoules or prefilled syringes in the original outer packaging to protect the solution from light. Midazolam solution may undergo photodegradation if exposed to prolonged direct light.
- Once opened: Midazolam Aguettant is intended for single use. Once the ampoule or syringe is opened, the contents should be used immediately. Any unused solution must be discarded and must not be stored for later use, as the product does not contain preservatives and the sterility of the solution can no longer be guaranteed once the container seal is broken.
- Diluted solutions: If midazolam is diluted for intravenous infusion (for example, in 0.9% sodium chloride or 5% dextrose), the diluted solution should be used within 24 hours at room temperature, or within 3 days if refrigerated at 2–8°C, unless specific stability data from the manufacturer indicates otherwise.
- Expiry date: Do not use Midazolam Aguettant after the expiry date printed on the ampoule and outer carton. The expiry date refers to the last day of that month.
- Keep out of reach: As a controlled substance with potential for misuse, midazolam must be stored securely in locked cabinets within clinical settings, with access restricted to authorized personnel in accordance with local controlled substance regulations.
- Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements for controlled substances and pharmaceutical waste.
Before administration, visually inspect the solution for particulate matter, discolouration, or damage to the container. Midazolam Aguettant solution should be clear and colourless to slightly yellow. Do not use the product if the solution appears cloudy, contains visible particles, or if the container is damaged.
What Does Midazolam Aguettant Contain?
Each millilitre of Midazolam Aguettant solution contains:
Active Ingredient
- Midazolam hydrochloride: Equivalent to midazolam 1 mg per ml. Midazolam hydrochloride is the water-soluble salt form of midazolam, a 1,4-benzodiazepine derivative with the chemical name 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine hydrochloride. The molecular formula is C18H13ClFN3·HCl, with a molecular weight of 362.25 g/mol.
Excipients (Inactive Ingredients)
- Sodium chloride: Used as a tonicity agent to make the solution isotonic with blood and tissues, reducing pain and tissue irritation during injection.
- Hydrochloric acid (dilute) and/or sodium hydroxide: Used for pH adjustment. The pH of the solution is adjusted to approximately 3.0–3.5, which is necessary to maintain midazolam in its water-soluble, open-ring form. At physiological pH (approximately 7.4), the ring closes and midazolam becomes lipophilic, facilitating rapid brain penetration.
- Water for injections: The vehicle for the injectable solution, meeting pharmacopoeial standards for sterile preparations.
Midazolam Aguettant is a preservative-free formulation. This means the solution does not contain antimicrobial preservatives such as benzyl alcohol or methylparaben. The absence of preservatives is particularly important for neonatal use, as benzyl alcohol has been associated with a potentially fatal “gasping syndrome” in premature neonates. Each container (ampoule or prefilled syringe) is intended for single patient use, and any unused solution must be discarded after opening.
The solution is available in various container sizes, typically including 5 ml (containing 5 mg midazolam), 10 ml (containing 10 mg midazolam), and 50 ml (containing 50 mg midazolam) presentations. The specific presentations available may vary by country and local marketing authorization.
Midazolam Aguettant can be diluted for intravenous infusion in 0.9% sodium chloride solution, 5% dextrose solution, Ringer’s solution, or Hartmann’s solution. The diluted solution should be prepared immediately before use. Midazolam should not be mixed with alkaline solutions (such as sodium bicarbonate), as precipitation may occur due to the pH-dependent solubility of midazolam. Always check specific compatibility data before combining with other intravenous drugs.
Frequently Asked Questions About Midazolam Aguettant
Midazolam Aguettant contains the same active substance (midazolam) as other midazolam-containing products available from various manufacturers. The primary difference lies in the concentration (1 mg/ml in this formulation), the container format (ampoules or prefilled syringes from Laboratoire Aguettant), and potentially the excipients used. The 1 mg/ml concentration is particularly useful for precise dose titration in paediatric patients and during procedural sedation, where smaller dose increments are required. Some other midazolam products are available at higher concentrations (e.g., 5 mg/ml), which are more suitable for adult IM injections or ICU infusions where larger total doses are administered.
The duration of clinical effect depends on the dose, route of administration, and patient factors. After a single IV bolus dose for conscious sedation, the peak effect typically lasts 15–30 minutes, with gradual recovery over 1–2 hours. However, residual effects on cognitive function, coordination, and memory may persist for several hours. In healthy adults, the elimination half-life is approximately 1.5–2.5 hours, meaning the drug is substantially eliminated within 6–12 hours. In elderly patients or those with hepatic impairment, the duration may be significantly prolonged. After ICU sedation with continuous infusion, recovery may take considerably longer due to drug accumulation in peripheral tissues.
Midazolam, like all benzodiazepines, has the potential for physical dependence and, less commonly, psychological dependence when used repeatedly or for prolonged periods. In the clinical setting, where midazolam is typically used for short-term procedural sedation, the risk of dependence is very low. However, in the ICU setting where midazolam may be administered as a continuous infusion for days or weeks, physical dependence can develop. Abrupt discontinuation after prolonged use may trigger withdrawal symptoms including anxiety, insomnia, tremors, and in severe cases, seizures. For this reason, midazolam is classified as a controlled substance in most countries, and gradual dose tapering is recommended after prolonged ICU use.
Yes, buccal midazolam (applied to the gums and inner cheek) is widely used as an emergency home treatment for prolonged convulsive seizures, particularly in children with epilepsy. However, the specific Midazolam Aguettant injectable formulation (1 mg/ml) is designed for use in hospital and supervised clinical settings. For home use in seizure emergencies, specially formulated buccal or oromucosal preparations with pre-measured doses are available (such as Buccolam). These dedicated formulations have specific instructions for non-medical caregivers, including parents and teachers. If your doctor prescribes buccal midazolam for seizure emergencies, you will receive specific training on how and when to administer it, and you will be given the appropriate formulation designed for home use.
Midazolam is well known for producing anterograde amnesia, which means it impairs the ability to form new memories after the drug is administered. This is actually a desirable effect in many clinical situations, as it helps patients avoid distressing memories of procedures. The degree of amnesia depends on the dose: at lower sedation doses, amnesia may be partial, while at higher doses it is typically complete. You may remember arriving for your procedure but have no recollection of the procedure itself or the immediate recovery period. This is normal and expected. Importantly, any information or instructions given to you while under the influence of midazolam may not be remembered, which is why written discharge instructions are always provided and reviewed with an accompanying adult.
Both midazolam and propofol are widely used for procedural sedation and ICU sedation, but they have different pharmacological profiles. Propofol has a faster onset (30–60 seconds IV) and faster recovery time compared with midazolam. Propofol provides smoother, more predictable sedation and is associated with less post-procedure nausea. However, propofol has a narrower therapeutic window (greater risk of transitioning from sedation to general anaesthesia), causes more significant hypotension, and has no specific reversal agent (unlike midazolam, which can be reversed with flumazenil). Midazolam provides superior amnesia and has better anxiolytic properties. For ICU sedation, current guidelines generally favour propofol or dexmedetomidine over midazolam due to lower rates of delirium and shorter time to extubation. The choice between agents depends on the clinical context, patient factors, and the specific requirements of the procedure or clinical situation.
References
- European Medicines Agency (EMA). Midazolam – Summary of Product Characteristics. Available via national medicines agencies within the EU. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Midazolam Injection – Prescribing Information. Revised 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: WHO Essential Medicines List.
- Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310–324. doi:10.1097/00000542-198503000-00017.
- Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (PADIS Guidelines). Crit Care Med. 2018;46(9):e825–e873. doi:10.1097/CCM.0000000000003299.
- National Institute for Health and Care Excellence (NICE). Sedation in under 19s: using sedation for diagnostic and therapeutic procedures. Clinical Guideline CG112. Updated 2024.
- McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2018;1(1):CD001905. doi:10.1002/14651858.CD001905.pub3.
- Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27–35.
- British National Formulary (BNF). Midazolam. National Institute for Health and Care Excellence (NICE). 2025.
- Olkkola KT, Ahonen J. Midazolam and Other Benzodiazepines. In: Schuttler J, Schwilden H, eds. Handbook of Experimental Pharmacology. Vol 182. Springer; 2008:335–360.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in anaesthesiology, intensive care medicine, and clinical pharmacology with extensive experience in sedation protocols and benzodiazepine pharmacology.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESICM, NICE).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.